Advertisement

PentaVision

Retinal Physician

Article

Photobiomodulation Therapy Delays Dry AMD Progression

Multiwavelength PBM approach shows visual acuity and disease morphology benefits.

By: Samuel Asanad, MD, David S. Boyer, MD
Retinal Physician March 1, 2025 Vol 22, Issue March 2025 Page(s): 8-11

Clinical Scorecard: Photobiomodulation Therapy Delays Dry AMD Progression

At a Glance

CategoryDetail
ConditionDry Age-Related Macular Degeneration (AMD)
Key MechanismsPhotobiomodulation (PBM) enhances mitochondrial function and reduces oxidative stress and inflammation.
Target PopulationPatients with early to intermediate dry AMD.
Care SettingClinical settings offering PBM therapy.

Key Highlights

  • PBM therapy shows benefits in visual acuity and disease morphology.
  • FDA approved LumiThera’s Valeda Light Delivery System for dry AMD.
  • PBM utilizes specific wavelengths (590 nm, 660 nm, 850 nm) for treatment.
  • Significant reduction in macular drusen volume observed after PBM.
  • Early intervention in dry AMD may prevent irreversible vision loss.

Guideline-Based Recommendations

Diagnosis

  • Identify dry AMD through clinical examination and imaging.

Management

  • Consider PBM therapy as a treatment option for early to intermediate dry AMD.

Monitoring & Follow-up

  • Regular follow-up to assess visual acuity and disease progression.

Risks

  • Limited long-term outcome data; potential for variability in patient response.

Patient & Prescribing Data

Individuals with early to intermediate dry AMD.

PBM therapy may stabilize disease and improve visual outcomes.

Clinical Best Practices

  • Utilize multiwavelength PBM for comprehensive treatment.
  • Monitor patients for response to therapy and adjust as necessary.
  • Educate patients on the potential benefits and limitations of PBM.

References